Tag: non-small cell lung cancer (NSCLC)

1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall survival versus comparator EGFR-TKIs with similar safety profiles. 2. Benefits appeared to extend across most predefined subgroups including sex, age, and smoking history, although there was...
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall survival versus comparator EGFR-TKIs with similar safety profiles. 2. Benefits appeared to extend across most predefined subgroups including sex, age, and smoking history, although there was...
Pembrolizumab is a monoclonal antibody against programmed cell death protein 1 (PD-1). Previous studies have shown that pembrolizumab is effective in prolonging survival in advanced non-small-cell lung cancer (NSCLC) with a PD1-ligand (PD-L1) tumor proportion score (TPS) of 50% or greater. In this randomized, open-label, phase 3 study, pembrolizumab...
1. In patients with non-small cell lung cancer (NSCLC), an analysis of clinical and genomic data from routine care replicated previously established relationships between driver mutations and response to therapy and between tumor mutation burden and response to immunotherapy 2. The study provides confirmation that a multi-institution clinicogenomic database may...
Association of Racial Disparities With Access to Kidney Transplant After the Implementation of the New Kidney Allocation System There are many reasons why a patient may be made inactive on the kidney transplant waiting list, including psychosocial or financial issues or medical comorbidities. This has important implications for a patient’s...